Plain-English translation of NCT07594015 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications — and — work together to treat endometrial cancer that has returned after initial treatment with chemotherapy and immunotherapy. The study focuses on a specific type of endometrial cancer (mismatch repair proficient) that doesn't respond well to standard treatments. Researchers want to see if this medication combination can slow or stop the cancer's growth and how safe it is for patients.
When endometrial cancer comes back after standard chemotherapy and immunotherapy, treatment options are very limited and outcomes are often poor. This trial exists to find a new treatment option that might help patients whose cancer has already resisted first-line therapy.
You likely qualify if…
You likely don't qualify if…
You would receive both medications together as your treatment, continuing for up to about 24 months or until your cancer progresses or you experience a severe side effect. Your total time in the study would be approximately 26 months, including follow-up visits and monitoring. You would need to attend regular clinic visits for blood tests, imaging scans, and check-ins with the research team to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States